✦ LIBER ✦

Clinical trials: rising costs limit innovation

✍ Scribed by S. Claiborne Johnston; Stephen L. Hauser

Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 65 KB
Volume: 62
Category: Article
ISSN: 0364-5134
DOI: 10.1002/ana.21329

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical trials confirm but don't innova

Clinical trials confirm but don't innovate—con

✍ Girling, David J. 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 32 KB

Randomised clinical trials became an essential part of clinical research in the 1940s. They have led to many important innovations in treatment in all areas of medicine, not least in oncology. Those of us involved in clinical research are aware, however, that the ways we are constrained to publish o

Clinical trials confirm but don't innova

Clinical trials confirm but don't innovate—pro

✍ D'Angio, Giulio J. 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 26 KB

Cost-effectiveness and lung cancer clini

Cost-effectiveness and lung cancer clinical trials

✍ Wei Du; Jaxk H. Reeves; Shirish Gadgeel; Judith Abrams; William P. Peters 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB

## Abstract ## BACKGROUND Lung cancer is the leading cause of cancer death in the U.S., with an estimated annual economic burden of $5 billion. Clinical trials offer innovative therapeutic options with potentially better outcomes, but their effects on health care costs are disputed. ## METHODS T

Innovations in the design of clinical tr

Innovations in the design of clinical trials in breast cancer

✍ Marvin Zelen 📂 Article 📅 1983 🏛 Springer US 🌐 English ⚖ 585 KB

Estimating country-specific cost-effecti

Estimating country-specific cost-effectiveness from multinational clinical trials

✍ Richard J. Willke; Henry A. Glick; Daniel Polsky; Kevin Schulman 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 102 KB 👁 2 views

Because costs and outcomes of medical treatments may vary from country to country in important ways, decision makers are increasingly interested in having data based on their own country's health care situations. This paper proposes methods for estimating country-specific cost-effectiveness ratios f

Bayesian estimation of cost-effectivenes

Bayesian estimation of cost-effectiveness ratios from clinical trials

✍ Daniel F. Heitjan; Alan J. Moskowitz; William Whang 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 194 KB 👁 2 views

Estimation of the incremental cost-effectiveness ratio (ICER) is difficult for several reasons: treatments that decrease both cost and effectiveness and treatments that increase both cost and effectiveness can yield identical values of the ICER; the ICER is a discontinuous function of the mean diffe